Posts by Mourabit Halima

During the 2024 CACA Integrated Esophageal Cancer Academic Conference, Dr. Shaoming Wang from the Cancer Hospital Chinese Academy of Medical Sciences gave an in-depth explanation of research progress on the burden of upper gastrointestinal cancer. During the conference, Oncology Frontier had the pleasure of interviewing Professor Wang to further explore his team’s latest research findings on the global lifetime risk of gastrointestinal cancer.

From September 25 to 29, 2024, the 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase important research advancements and trends in the field, both domestically and internationally. For over two decades, CSCO has been at the forefront of clinical oncology development in China, and numerous experts and scholars have played integral roles in its evolution, growing along with CSCO. To honor this journey, Oncology Frontier has established a special column, "Growing Together with CSCO," to reflect on these experiences with Chinese scholars. In this inaugural issue, we are pleased to interview Dr. Zefei Jiang, Vice President and Secretary General of CSCO and a professor at the The Fifth Medical Center of Chinese PLA General Hospital, who shares his personal journey of growth with CSCO and highlights the exciting features of the 2024 CSCO Conference.

As one of the world's largest and most academically prestigious clinical oncology conferences, the 2024 European Society for Medical Oncology (ESMO) conference, held from September 13 to 17 in Barcelona, drew global attention. The conference revealed several important clinical study results in upper gastrointestinal tumors. Dr. Filippo Pietrantonio, an oncologist from the National Cancer Institute in Milan, Italy, shared his insights in an exclusive interview with Oncology Frontier.

From October 19-20, 2024, the first stop of the "St. Gallen Breast Cancer Conference China Tour" was held in Nanjing. This series of conferences is organized by the Breast Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), with support from the Beijing Xisike Clinical Oncology Research Foundation, the Beijing Kexin Medical Development Foundation, and the Jiangsu Anti-Cancer Association. It is hosted by Jiangsu Provincial People's Hospital. SGBCC President, Prof. Michael Gnant, personally attended the event, facilitating the exchange of the latest advancements between European, Japanese, and Chinese breast cancer experts. Prof. Zefei Jiang, the President-Elect of CSCO and a member of the St. Gallen Breast Cancer International Consensus Panel, shared his insights and expressed his expectations for future cooperation between SGBCC and CSCO.

From October 15-17, 2024, the 16th Shanghai Breast Reconstruction Conference and 5th Shanghai Breast Reconstruction Nursing Forum were successfully held, organized by the Chinese Anti-Cancer Association's Breast Cancer Integration Committee and the Shanghai Anti-Cancer Association and hosted by Fudan University Shanghai Cancer Center. The conference focused on the status of breast conservation and reconstruction in China, promoting international exchanges and expanding achievements in breast reconstruction to preserve health and beauty for breast cancer patients. During the conference, Oncology Frontier interviewed the conference chairman, Dr. Jiong Wu from Fudan University Shanghai Cancer Center, to explore the current and future trends in breast conservation, reconstruction, and the latest advances in neoadjuvant immunotherapy in breast cancer treatment.

n recent years, breast cancer treatment in China has undergone a remarkable transformation, from drug accessibility to treatment paradigms, aligning more closely with global standards. At the 2024 SIBCS conference, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, delivered an insightful presentation on “Major Clinical Trial Achievements in China’s Breast Cancer Treatment,” highlighting significant advancements in the field. Following the conference, Oncology Frontier interviewed Dr. Liu, who noted the increasing prominence of China’s original clinical research on the global stage. He pointed out that China is no longer simply following international developments but is now keeping pace, and in some areas, even leading, providing new hope for breast cancer patients worldwide.